Potential Inhibitors of SARS-CoV-2 Main Protease (M^pro) Identified from the Library of FDA-Approved Drugs Using Molecular Docking Studies.

ABSTRACT: The Corona Virus Infectious Disease-2019 (COVID-19) outbreak originated at Wuhan, China, in December 2019. It has already spread rapidly and caused more than 6.5 million deaths worldwide. Its causal agent is a beta-coronavirus named SARS-CoV-2. Many efforts have already been made to develop new vaccines and drugs against these viruses, but over time, it has changed its molecular nature and evolved into more lethal variants, such as Delta and Omicron. These will lead us to target its more-conserved proteins. The sequences' BLAST and crystal structure of the main protease M^pro suggest a high sequence and structural conservation. M^pro is responsible for the proteolytic maturation of the polyprotein essential for the viral replication and transcription, which makes it an

SUBMITTER: Verma DK 

PROVIDER: S-EPMC9856154 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature